News Detail
Maryland, 19 Dec 2017: The U.S. Food and Drug Administration (FDA) is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) concerning gadolinium remaining in patients’ bodies, including......
View Details
Source : US FDA Safety Anouncement
Related News
- Not many equipped to make Covaxin (17-05-2021)
- Hester Biosciences in talks with Bharat Biotech for production of Covaxin via tech transfer (17-05-2021)
- Chemist is liable for wrong medication (17-05-2021)
- Time to make laws dealing with hoarding, black marketing more strict (17-05-2021)
- States, UTs allotted Remdesivir until May 23 to ensure 'adequate availability': Sadananda Gowda (16-05-2021)
- CBI arrests two CDSCO medical device officers in Rs 3.50 lakh bribery case (16-05-2021)
- Are Hospitals Prescribing Unscientific Coronil To Covid Patients? (16-05-2021)
- Misuse of steroids major cause behind mucormycosis infection: AIIMS chief (16-05-2021)
- Bareilly medical equipment supplier booked for overpricing (16-05-2021)
- Bareilly medical equipment supplier booked for overpricing (16-05-2021)